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Male breast carcinoma is an extremely rare malignancy com-
prising less than 1% of all breast cancers and less than 1.5%
of all malignancies in men [1,2]. The diagnosis is usually
delayed until advanced stage, accounting for poor outcome
[3]. The most common histologies in male breast carcinoma
are infiltrating ductal carcinomas (about 74–95%) and papil-
lary carcinoma (3–4%) [3,4]. Lobular carcinoma represents
only 1% of all these tumors [5,6]. We here present a case of
locally advanced lobular carcinoma of male breast.
Case report
A sixty year old male presented with right breast nodule, pro-
gressively increasing in size since 4 months. He had a historyof remission and recurrence of a right breast swelling since
two years. He also complained of pain in right leg since
20 days. He was married and had 2 live and healthy children.
There were no associated comorbidities or history of
hormonal use. He used to chew tobacco since the age of
20 years.
On clinical examination there was an irregular, hard, pain-
less, well-defined, swelling fixed to the chest wall, measuring
8  4 cm and involving the supra-areolar medial and lateral
quadrants. Overlying skin was hyper pigmented and there were
satellite nodules involving the surrounding skin. Ipsilateral
axillary lymph nodes were palpable and mobile.
Histopathological findings
Biopsy from the breast lump showed features of an invasive
lobular carcinoma. Tumor cells were arranged in cords and
trabeculae within the stroma forming an Indian-file pattern
(Fig. 1A). The tumor cells were small, showing mild
pleomorphism with scant to moderate amount of eosinophilic
to clear cytoplasm, round nucleus with vesicular chromatin
Figure 1 Photomicrograph showing 200 (A) and 400 (B) view of tumor cells (both H&E stained sections).
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immunohistochemistry, tumor cells showed strong positivity
for Estrogen receptors (Allred score 8), progesterone receptors
(Allred score 8) and negativity for Her-2/neu receptors. Cell
membrane was stained negative for E-cadherin. (Fig. 2)
PET-CT done for metastatic work-up showed an FDG avid
mass (3.5  8.0 cm) in the right breast, infiltrating the chest
wall in the central region with involvement of the overlying
skin and multiple FDG avid satellite nodules. Multiple FDG
avid right axillary lymph nodes and extensive skeletal metas-
tases were present (Fig. 3).Figure 2 Immunohistochemistry: Positive nuclear staining for E
E-cadherin (D).Disease was staged clinically as cT4N1M1 (stage IV).
Treatment
Palliative radiotherapy was given to right breast nodule, skele-
tal weight bearing and painful areas. He received palliative
chemotherapy with cyclophosphamide 500 mg/m2, epirubicin
80 mg/m2 and 5-FU 500 mg/m2. Post 6 cycles of chemotherapy
PET-CT done for response assessment showed partial response
to treatment. Then the patient was started on tamoxifen 20 mg
daily.R (A) and PR (B), negative staining for Her-2/neu (C), and
Figure 3 PET images showing the primary disease in breast (A) and metastases at multiple skeletal sites (B and C).
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The majority of patients with male breast cancer present
with a palpable mass and/or visible nipple changes [5].
The median age at diagnosis is in 6th decade [4]. Although
some factors favor early detection, like thin soft tissue, the
interval between first complaints and diagnosis is usually
longer, so the tumor is advanced in most cases at the time
of initial diagnosis, contributing to poorer outcome. Because
of its diffuse growth pattern and tendency to form lesions
with opacity equal to or less than that of the breast par-
enchyma, invasive lobular carcinoma can be extremely diffi-
cult to detect mammographically, potentially adding to
delay in diagnosis when compared to invasive ductal carci-
noma [7].
The predisposing factors for male breast cancer are
mostly unknown. Numerous etiologies have been elucidated,
such as genetic mutations, especially BRCA2, and conditions
associated with an imbalance between estrogen and testos-
terone. Certain medications, such as cimetidine [8], are
hypothesized to increase the risk for male breast cancer
via an estrogenic mechanism. Some other associated risk fac-
tors are undescended testes, congenital inguinal hernia,
orchiectomy, orchitis, testicular injury, infertility and Kline-
felters syndrome [2,6]. Mutations of either the BRCA1 or
the BRCA2 gene are thought to be found in 4–40% ofmen with breast cancer, with BRCA2 mutation being more
frequent [5]. A positive family history of breast carcinoma
may be an important contributor [9]. Although tobacco
smoking and alcohol do not appear to be carcinogenic for
male breast cancer, [10] our patient had a significant history
of tobacco chewing.
Although lobular carcinoma of the female breast is rela-
tively common, comprising approximately 15% of all cases
of female breast cancer, in males this histopathologic pattern
is exceedingly rare, because lobules and acini are not found
in normal male breast tissue [11]. Estrogen has a profound
effect on male breast tissue and is liable to stimulate forma-
tion of acini and lobules identical to those of female breast.
The first case of invasive lobular carcinoma in a male
patient without known estrogen exposure was described in
1989 [12]. Evaluation of 2537 male breast cancer cases from
the SEER database between 1973 and 1998 found 1.5%
invasive lobular carcinomas [2]. The highest percentage,
4.2%, was noted by Nahleh et al. [3] who analyzed the
Veterans Affairs Central Cancer registry with 612 male
breast cancer patients. But none of these studies were able
to review the original pathology for confirmation of the lob-
ular histology.
Treatment of male breast cancer remains controversial. The
lower incidence of invasive lobular carcinoma in men likely
explains the lack of studies focusing on the treatment of this
58 R. Upadhyay et al.tumor type. Clinical knowledge of male breast cancers overall
derives mostly from single institutional retrospective studies
and from database studies. In general, most principles are
similar to those of female breast cancer. Total mastectomy
with axillary dissection is the optimum local therapy for carci-
noma of the male breast [13]. Radiation therapy does appear
to be effective in preventing local recurrences in male patients,
but all studies have been underpowered to address the question
of a potential survival benefit [14]. Male breast cancer patients
do tend to be treated with radiation therapy after mastectomy
more often than females, perhaps because they are more likely
to have nipple or skin involvement [15]. Studies have shown
that the presence of infiltrating lobular histology should not
influence decisions regarding local radiation therapy [16]. Pal-
liative radiotherapy has a proven role in management of meta-
static disease [17]. Although the evidence is limited, most
studies support a benefit for both adjuvant chemotherapy
and tamoxifen in male breast cancer, particularly when the
prognosis is poor [18]. Carcinomas of the male breast have
higher rate of hormone receptor positivity (80–85%) than do
those of the female breast when matched for tumor stage,
grade and patient age [5].
Our patient also presented at an advanced stage of disease
with multiple metastases. We treated our patient with pallia-
tive radiotherapy, chemotherapy, followed by tamoxifen in
view of ER positivity. There was partial response after
chemotherapy. On tamoxifen there was excellent disease con-
trol with palliation of symptoms. He is still alive after
20 months of initial diagnosis.
Conclusion
Invasive lobular carcinoma of male breast is a rare entity and
poses as a diagnostic and therapeutic difficulty in view of its
uncommon histology and late presentation. This diagnosis
should be suspected early and treated aggressively with
multimodality approach. Further large adequately powered
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